Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCSMANC: Breast Cancer Shrinkage Modes After Neoadjuvant Chemotherapy
NCT01917578Phase 3Unknown
- Sponsor
- Shandong Cancer Hospital
- Start
- Aug 2008
- Primary completion
- Mar 2014
- Modality
- Antibody Conjugates, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cyclophosphamide, pegylated liposomal doxorubicin, docetaxel, Paclitaxel Micelles for Injection, fluorouracil and 3 more in breast cancer, sponsored by Shandong Cancer Hospital. Status: unknown.
02
Drugs
cyclophosphamidepegylated liposomal doxorubicindocetaxelPaclitaxel Micelles for Injectionfluorouracil
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01917578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01917578.